hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing of vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, it offers specialized virology and immunology laboratory, which offers a suite of services to support pre-clinical and clinical respiratory drug; and vaccine discovery and development. Further, the company provides pre­clinical and early clinical research services; sales and marketing services; data management; and statistics services, as well as drug development consultancy and services. The company was formerly known as Open Orphan Plc and changed its name to hVIVO plc in October 2022. hVIVO plc is headquartered in London, the United Kingdom.

hVIVO plc

Dr. Yamin Mohammed Khan Ph.D.

CEO & Director

Mr. Stephen  Pinkerton

CFO & Executive Director

Mr. Andrew  Catchpole

Chief Scientific Officer

Dr. Maurice N. Treacy Ph.D.

Chief Commercial Officer

Ms. Teja  Marathe-Sarvadikar

Head of QA

HVO's next earnings is on May 13, 2025 (After Market Close)

HVO's latest dividend is 0.002 GBP on April 18, 2024

hVIVO plc (HVO) Stock Analysis, Discussion Forum and Financial Metrics - LSE Exchange

hVIVO plc (HVO) Earnings Report Date and History | LSE

HVO's next earnings is on May 13, 2025 (After Market Close)

When is the earnings report for HVO?

HVO Earnings History

HVO's latest dividend is 0.002 GBP on April 18, 2024

HVO Stock Discussion Forum and Message Board

News for LSE: HVO